Accuray Newsroom

Earnings Preview: Accuray to Report Financial Results Post-market on April 30

Moomoo NewsApr 24 21:00 ET

Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

PR NewswireApr 16 16:05 ET

Healthcare Stocks Aren't a Shelter From the Tariff Storm -- Barrons.com

Barron'sApr 9 12:04 ET

Trump Defends Tariffs, Announces Pharmaceutical Levies Coming Soon

WSJApr 8 21:11 ET

Pharma Stocks Have Risk of U.S. Tariffs Priced In -- Market Talk

WSJApr 8 03:27 ET

Accuray CyberKnife Platform Featured in New Studies Showcasing Its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

PR NewswireApr 3 07:35 ET

The "Liberation Day" of Trump's tariffs is approaching, and the pharmaceutical Industry may not be among the targets.

According to reports, President Trump of the USA is expected to announce a series of broader tariff measures on local time April 2 (Wednesday), which will not include any specific details on Pharmaceutical tariffs.

Zhitong FinanceApr 1 08:50 ET

Accuray Incorporated (NASDAQ:ARAY): When Will It Breakeven?

Yahoo FinanceMar 30 08:44 ET

Following the chips and AI, the USA may consider launching a national strategy for Siasun Robot&Automation.

① USA companies urge the government to launch a Siasun Robot&Automation national strategy to promote the development of the smart robot Industry and drive the development of next-generation robots in Global competition; ② The USA Association for Advanced Automation recommends that the government adopt tax incentive measures, provide federal funding, and establish a new federal robotics office to expand production capacity and promote the application of AI.

cls.cnMar 27 02:17 ET

The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.

Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.

Zhitong FinanceMar 18 03:00 ET

Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup

Dow JonesMar 17 16:53 ET

Accuray (NASDAQ:ARAY) Is Experiencing Growth In Returns On Capital

Yahoo FinanceMar 13 07:11 ET

Accuray to Participate at 37th Annual Roth Conference

PR NewswireMar 12 07:30 ET

ZAP Surgical Unveils the ZAP-Axon Radiosurgery Planning System

BusinesswireMar 11 07:17 ET

Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Stock's 25% Plummet

Simply Wall StMar 8 07:19 ET

Morgan Stanley Fund: Humanoid robots will gradually enter the mass production phase by 2025.

Currently, the humanoid robot industry both domestically and internationally is mainly divided into three major forces: automotive companies, robot companies, and Internet companies. The primary demand for humanoid robots such as those from Tesla is the ability for scaled production and cost reduction.

Zhitong FinanceMar 3 06:55 ET

Goldman Sachs' research throws cold water on the situation: the turning point for humanoid robot technology remains unclear, and meaningful applications will take at least another five years!

Goldman Sachs believes that the humanoid robot H1 has only 19 degrees of freedom, making it still unable to handle complex and detailed tasks. At least in the next 2-3 years, it will be difficult for humanoid robots to achieve the same work efficiency as human workers. Meaningful applications are not expected for another 5-10 years.

wallstreetcnFeb 27 07:49 ET

The Past Three Years for Accuray (NASDAQ:ARAY) Investors Has Not Been Profitable

Yahoo FinanceFeb 24 14:18 ET

Goldman Sachs Siasun Robot&Automation deep research (3): Humanoid robots may be nearing mass production, with turning points emerging in three areas.

Humanoid robots are rapidly developing, but overall technology has not yet met the requirements for large-scale application in the industrial or Consumer sectors. Goldman Sachs believes that the turning point for humanoid robot technology may occur in three areas: solving multiple general tasks, high success rates and sustained robustness, and rapid reasoning. Currently, the development of humanoid robots still faces some obstacles, such as the lack of original data needed for training.

wallstreetcnFeb 20 22:32 ET

Home Healthcare Inflation Is Stubbornly High -- WSJ

WSJFeb 12 12:30 ET